PCM
AMED

Peregrine Capital Management’s Amedisys AMED Stock Holding History

Peregrine Capital Management’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-121,111
Closed -$7.31M – 307
2018
Q1 		$7.31M Buy
+121,111
New +$6.9M 0.18% 201

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Peregrine Capital Management's AMED Position: Q2 2018 in Review

Peregrine Capital Management sold out of Amedisys (AMED) in Q2 2018, closing a stake of 121,111 shares — an estimated $7.31M sold.

Peregrine Capital Management first reported a position in AMED in Q1 2018 and held it in 1 quarter. The position peaked at $7.31M in Q1 2018. 216 funds tracked by Wall St. Rank hold AMED as of Q2 2018.

  • Peregrine Capital Management reported no remaining Amedisys position as of Q2 2018 after selling out during the quarter.
  • Peregrine Capital Management sold 121,111 Amedisys shares in Q2 2018, an estimated $7.31M.
  • Peregrine Capital Management first reported a position in Amedisys in Q1 2018 and held it in 1 quarter.
  • Peregrine Capital Management's Amedisys position peaked at $7.31M in Q1 2018.
  • 216 funds tracked by Wall St. Rank held Amedisys as of Q2 2018.

Based on Peregrine Capital Management's 13F filing for Q2 2018, filed 12 Jul 2018.